The largest research peptide vendor voluntarily closed on March 6, 2026. But the FDA just reclassified 14 peptides to Category 1 — opening a legal path that didn't exist before.
The Full Story
The shutdown wasn't sudden — it was the culmination of a regulatory shift that reshaped the entire peptide market.
Peptide Sciences was widely regarded as the most reputable gray-market research peptide vendor in the United States. For years, they set the standard for third-party testing, Certificates of Analysis, and product consistency.
But the peptide landscape changed dramatically in early 2026 — and Peptide Sciences chose to close rather than continue operating in an increasingly regulated market.
Regulatory Shift
This is the most significant regulatory change for peptides in years. Here's what it actually means.
The FDA maintains a list of substances that compounding pharmacies are restricted from producing. In 2023–2024, 19 popular peptides were added to this list, effectively cutting off the legal supply chain.
In early 2026, the FDA reversed course on most of them. 14 of 19 peptides were reclassified to Category 1 — the least restrictive category, which allows licensed 503A and 503B compounding pharmacies to produce them under a physician's prescription.
Licensed compounding pharmacies can legally produce these peptides. You need a physician's prescription. The pharmacy must follow USP <797> sterile compounding standards. Products are tested and regulated.
503A pharmacies fill individual prescriptions. 503B outsourcing facilities produce larger batches under more stringent FDA oversight. Both can now compound Category 1 peptides.
A prescription from a licensed physician or telehealth provider. Many peptide-focused clinics and anti-aging practices can prescribe Category 1 compounds. Some offer telehealth consultations.
Five of the original 19 peptides remain in higher restriction categories and are not available through compounding pharmacies. Check our FDA Status Tracker for the current list.
⚠️ This list reflects the reclassification as announced. Verify current status on our FDA Status Tracker as regulatory decisions may evolve.
Your Options
The peptide market has split into two distinct paths. Here's an honest comparison.
Buyer's Guide
Whether you go the pharmacy route or research vendor route, these are the quality markers that matter.
Bottom Line
Stay Informed
Free tools to help you navigate the new peptide landscape.
Common Questions
Peptide Sciences voluntarily ceased operations on March 6, 2026. The shutdown followed the FDA's reclassification of 14 previously restricted peptides to Category 1, which made them available through licensed compounding pharmacies. This regulatory shift made the gray-market research peptide model less viable as legal alternatives became widely available.
14 of 19 previously restricted peptides were reclassified, including BPC-157, TB-500, GHK-Cu, KPV, CJC-1295, Ipamorelin, Tesamorelin, Sermorelin, PT-141, DSIP, Epithalon, Thymalin, Selank, and Semax. Check our FDA Status Tracker for the most current information.
Yes. The Category 1 reclassification means 14 previously restricted peptides can now be obtained through licensed compounding pharmacies with a physician's prescription. This is the recommended legal path. Many telehealth providers and anti-aging clinics can facilitate prescriptions.
Compounding pharmacies are licensed, FDA-regulated facilities that prepare medications under a physician's prescription. They follow USP <797> and <800> standards for sterile compounding. Research peptide vendors sell peptides labeled "for research purposes only" and operate without the same regulatory oversight, testing requirements, or legal protections.
Look for batch-specific COAs with HPLC purity data (≥98%), third-party testing from labs like Janoshik Analytical, LCMS molecular identity confirmation, endotoxin testing for injectables, and sterility testing. Read our complete quality testing guide for detailed instructions.
In early 2026, the FDA reclassified 14 of 19 previously restricted peptides to Category 1 — the least restrictive category. This means licensed 503A and 503B compounding pharmacies can legally compound them with a physician's prescription. It was a major regulatory reversal announced by RFK Jr. that moved many peptides from gray-market-only to legally accessible through the healthcare system.
Yes, other gray-market research peptide vendors continue to operate. However, with Category 1 reclassification making many peptides legally available, the compounding pharmacy path is now recommended for most users. If you use research vendors, rigorously verify COAs and third-party testing, and understand you're operating in a legal gray area with less consumer protection.
Whether you source from a compounding pharmacy or elsewhere, you'll need proper supplies for safe handling.
Affiliate links help support MeetPeptide at no extra cost to you.
Continue Reading
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Disclaimer: This page is for educational and informational purposes only. It is not medical advice, legal advice, or a recommendation to buy from any specific vendor or pharmacy. Peptide regulations vary by jurisdiction and are subject to change. Always consult with a qualified healthcare provider before starting any peptide protocol. Verify current FDA regulatory status through official channels. Data on this page reflects information available as of March 2026.
MeetPeptide Home · Research Library · FDA Tracker · Reconstitution Guide